Molecular Markers of Prognosis and Response to Therapy in Breast Cancer

The goal is to understand hereditary breast cancer in greater detail leading to a prospective clinical trial (one of the first of its kind in the country).

Dr. Rasmussen will: 

1) expand clinical subtypes and refine genetic signatures for each subtype of previous gene expression profiles

2) design a prospective clinical trial based on these profiles, and

3) include known familial and hereditary breast cancer cases in order to determine which clinical subtype they belong to. Gene expression profiling promises to provide much more powerful diagnostic, diagnostic and therapeutically predictive tests and will influence patient care in the very near future.

Organization: 
Maine Center for Cancer Medicine
Researcher: 
Karen Rasmussen, Ph. D
Grant Amount Given: 
$70,500
Year Issued: 
2004
Period: 
Annual
Grant Category: 
Research
Types of Cancer: 
Breast
Grant Duration: 
1 Year Pilot Grant

Maine Cancer Foundation Grants to this Organization:

Year Program Amount Category Organization
2010 Evaluating MicroRNA's as Prognostic Determinants in Stage II Colon Cancer $78,000 Research Maine Center for Cancer Medicine
2008 Colorectal Cancer Screenings $6,839 Screening Maine Center for Cancer Medicine
2007 Toolkit for Colorectal Cancer $4,800 Education Maine Center for Cancer Medicine
2006 Cancer Risk and Prevention $1,862 Education Maine Center for Cancer Medicine
2006 Molecular Predictors of Iressa Response in Lung Cancer Patients $68,241 Research Maine Center for Cancer Medicine
2004 Molecular Markers of Prognosis and Response to Therapy in Breast Cancer $70,500 Research Maine Center for Cancer Medicine
2003 Molecular Indicators of Prognosis and Response to Therapy in Breast Cancer $60,700 Research Maine Center for Cancer Medicine
2001 Cancer Genetics Research $87,000 Research Maine Center for Cancer Medicine